StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 38.0 %

Eagle Pharmaceuticals stock opened at $0.90 on Thursday. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $9.10. The business has a fifty day moving average price of $1.62 and a 200-day moving average price of $3.58.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of EGRX. Creative Planning purchased a new position in shares of Eagle Pharmaceuticals during the 3rd quarter valued at $59,000. Mackenzie Financial Corp bought a new position in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals during the second quarter worth approximately $65,000. Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $76,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.